Development of EQA for fusion gene testing
Targeted therapies available for the treatment of cancer are increasingly being considered as standards of care in routine clinical practice. These therapies, such as Crizotinib for non-small cell lung cancer and Cextuximab for colorectal cancer are recommended for single tumour types. However, third generation therapies targeting fusion genes have received licensing approval and are being read more…
Expression of interest to develop an EQA for cfDNA multi-target testing
UPDATE: The deadline is passed (21 February). For further information, please contact executive@iqnpath.org IQN Path invites expressions of interest from all EQA provider members to collaborate to develop and deliver EQA to assess the standard of testing circulating free tumour DNA (cfDNA) for multiple biomarkers in plasma. The first IQN Path supported activity was a collaboration read more…
New article: Biomarker testing in oncology
Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL In personalized medicine, predictive biomarker testing is the basis for an appropriate choice of therapy for patients with cancer. An important tool for laboratories to read more…
Update on the project Tumor Mutation Burden (TMB): from Recommendations for Testing to EQA Schemes
Conflicting results have been reported on the potential role of Tumor Mutational Burden (TMB) as predictive biomarker for immune checkpoint inhibitors. However, the recent approval of TMB as agnostic biomarker for pembrolizumab in previously treated patients with solid tumors is increasing the interest of laboratories to provide this test. In this scenario, the harmonization of read more…
Welcome back to NordiQC. Now offers PD-L1 IHC Fit-For-Purpose Proficiency Testing
PD-L1 IHC testing has a significant impact on patient eligibility for tailored specific immune oncology and require high diagnostic accuracy. This also underlines the need of appropriate EQA methods to evaluate the performance of PD-L1 IHC testing among the participating laboratories. At present, PD-L1 IHC testing is based on the “3D-approach” aligning Drug, Disease and read more…
Our Experience during the Covid-19 Pandemic, by IQNPath Board Member Jingxin Qiu
Jingxin Qiu, Roswell Park Comprehensive Cancer Center, Buffalo, New York I’d first like to share a bit of background about our center. Roswell Park Comprehensive Cancer Center was established by Dr. Roswell Park in 1898 in Buffalo, New York — the first institution in the world to focus exclusively on cancer research. Over the years, Roswell read more…
IQN Path free access to CBQAReadout.ca
IQN Path is pleased to announce and endorse two new CBQAReadout modules including VENTANA PD-L1 (SP142) Assay, NSCLC, atezolizumab (3 hours) and VENTANA PD-L1 (SP263) Assay, NSCLC, nivolumab (3 hours). VENTANA PD-L1 (SP142) Assay, triple negative breast cancer, atezolizumab and nab-paclitaxel (2 hours) module will be open on June 1st, 2020. We will update you regularly read more…
Proficiency testing CBQA Readout
An academic proficiency testing program for the assessment of pathologists’ and technologists’ accuracy of biomarker readout IQN Path is pleased announce and endorse CBQAReadout.com. CBQAReadout.com (www.cbqareadout.ca) is a new proficiency testing (PT) program for pathologists’ readouts. The primary focus of this new PT program are predictive immunohistochemistry biomarkers such as PD-L1. In the future, the read more…